The predictive role of thrombocytosis in benign, borderline and malignant ovarian tumors

References

• The Global Cancer Observatory. World: incidence, mortality and prevalence by cancer site 2018. Lyon, France: International Agency for Research on Cancer; 2019. [cited 2019 May 11]; Available from: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
   Google Scholar
• Cancer Research UK. Ovarian cancer statistics. Oxford, UK: Cancer Research UK. [cited 2019 May 11]; Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-One
   Google Scholar
• Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68(4):284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Hartman CA, Juliato CR, Sarian LO, Toledo MC, Jales RM, Morais SS, Pitta DD, Marussi EF, Derchain S. Ultrasound criteria and CA 125 as predictive variables of ovarian cancer in women with adnexal tumors. Ultrasound Obstet Gynecol 2012;40(3):360–366. doi:10.1002/uog.11201
   PubMed Web of Science ®Google Scholar
• Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72(1):23–27.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998;43(4):387–392.
   PubMed Web of Science ®Google Scholar
• Lehtovirta P, Apter D, Stenman UH, Serum CA. 125 levels during the menstrual cycle. Br J Obstet Gynaecol 1990;97(10):930–933. doi:10.1111/j.1471-0528.1990.tb02449.x
   PubMedGoogle Scholar
• Chen FP, Soong YK, Lee N, Lo SK. The use of serum CA-125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstet Gynecol Scand 1998;77(6):665–670. doi:10.1034/j.1600-0412.1998.770615.x
   PubMed Web of Science ®Google Scholar
• Wang ML, Huang Q, Yang TX. IgE myeloma with elevated level of serum CA125. J Zhejiang Univ Sci B 2009;10(7):559–562. doi:10.1631/jzus.B0820399
   PubMed Web of Science ®Google Scholar
• Laki K. Our ancient heritage in blood clotting and some of its consequences. Ann N Y Acad Sci 1972;202:297–307. doi:10.1111/nyas.1972.202.issue-1
   PubMed Web of Science ®Google Scholar
• Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract 2017;67(659):e405–e413. doi:10.3399/bjgp17X691109
   PubMed Web of Science ®Google Scholar
• Abdulrahman GO Jr, McKnight L, Lutchman Singh K. The risk of malignancy index (RMI) in women with adnexal masses in Wales. Taiwan J Obstet Gynecol 2014;53(3):376–381. doi:10.1016/j.tjog.2014.05.002
   PubMed Web of Science ®Google Scholar
• Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004;198(5):737–741. doi:10.1016/j.jamcollsurg.2004.01.022
   PubMed Web of Science ®Google Scholar
• Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, Noh SH. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 2012;38(7):562–567. doi:10.1016/j.ejso.2012.04.009
   PubMed Web of Science ®Google Scholar
• Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189(3):278–282. doi:10.1016/j.amjsurg.2004.11.014
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004;10(17):2472–2477. doi:10.3748/wjg.v10.i17.2472
   PubMed Web of Science ®Google Scholar
• Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer 2013;44(3):293–304. doi:10.1007/s12029-013-9491-9
   PubMedGoogle Scholar
• Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 2007;79(2):111–116. doi:10.1159/000106322
   PubMed Web of Science ®Google Scholar
• Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996;9(9):1826–1830. doi:10.1183/09031936.96.09091826
   PubMed Web of Science ®Google Scholar
• Soonthornthum T, Suraseraneewong V, Kengsakol K, Wijaithum K, Kasemsan P, Prommatt S. Thrombocytosis in advanced epithelial ovarian cancer. J Med Assoc Thai 2007;90(8):1495–1500.
   PubMedGoogle Scholar
• Zeimet AG, Marth C, Müller-Holzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994;170(2):549–554. doi:10.1016/S0002-9378(94)70225-X
   PubMed Web of Science ®Google Scholar
• Menczer J, Schejter E, Geva D, Ginath S, Zakut H. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 1998;19(1):82–84.
   PubMed Web of Science ®Google Scholar
• Yenen MC, Alanbay I, Aktürk E, Ercan CM, Coksuer H, Karaşahin E, Ozan H, Dede M. Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor. Eur J Gynaecol Oncol 2012;33(2):168–173.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Ovarian cancer: recognition and initial management [internet]. London, UK: National Institute for Health and Care Excellence; 2011. [updated 2017 Dec, cited 2019 Mar 19]. Available from: https://www.nice.org.uk/guidance/cg122/resources/ovarian-cancer-recognition-and-initial-management-pdf-35109446543557
   Google Scholar
• Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, Chang-Claude J, Bergmann M, Steffen A, Bamia C. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer 2015;112(7):1257–1265. doi:10.1038/bjc.2015.22
   PubMed Web of Science ®Google Scholar
• Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS One 2018;13(10):e0205000. doi:10.1371/journal.pone.0205000
   PubMed Web of Science ®Google Scholar
• Agoston AT, Srivastava A, Zheng Y, Bueno R, Odze RD, Szallasi Z. Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma. Pathology 2017;49(5):471–475. doi:10.1016/j.pathol.2017.04.001
   PubMed Web of Science ®Google Scholar
• Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology 2012;59(118):1687–1690. doi:10.5754/hge12277
   PubMedGoogle Scholar
• Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U, Briganti A, Damiano R, Montorsi F, Colombo R. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. Anticancer Res 2014;34(6):3225–3230.
   PubMed Web of Science ®Google Scholar
• Chechia A, Attia L, Temime RB, Makhlouf T, Koubaa A. Incidence, clinical analysis, and management of ovarian fibromas and fibrothecomas. Am J Obstet Gynecol 2008;199(5):473.e1-4. doi:10.1016/j.ajog.2008.03.053
   PubMed Web of Science ®Google Scholar
• McCluggage WG, Sloan JM, Boyle DD, Toner PG. Malignant fibrothecomatous tumour of the ovary: diagnostic value of anti-inhibin immunostaining. J Clin Pathol 1998 Nov;51(11):868–871. doi:10.1136/jcp.51.11.868
   PubMed Web of Science ®Google Scholar
• Leung SW, Yuen PM. Ovarian fibroma: a review on the clinical characteristics, diagnostic difficulties, and management options of 23 cases. Gynecol Obstet Invest 2006;62(1):1–6. doi:10.1159/000091679
   PubMed Web of Science ®Google Scholar
• Shinagare AB, Meylaerts LJ, Laury AR, Mortele KJ. MRI features of ovarian fibroma and fibrothecoma with histopathologic correlation. AJR Am J Roentgenol 2012;198(3):W296–303. doi:10.2214/AJR.11.7221
   PubMed Web of Science ®Google Scholar
• Lager TW, Roetman JJ, Kunkel J, Thacker M, Sheets JN, Egland KA, Miles CM, Larson MK, Gubbels JAA. Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells. Platelets 2018;29(8):834–837. doi:10.1080/09537104.2018.1530345
   PubMed Web of Science ®Google Scholar
• Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366(7):610–618. doi:10.1056/NEJMoa1110352
   PubMed Web of Science ®Google Scholar